Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line.
Chikungunya virus-like particles (VLPs) have potential to be used as a prophylactic vaccine based on testing in multiple animal models and are currently being evaluated for human use in a Phase I clinical trial. The current method for producing these enveloped alphavirus VLPs by transient gene expression in mammalian cells presents challenges for scalable and robust industrial manufacturing, so the insect cell baculovirus expression vector system was evaluated as an alternative expression technology. Subsequent to recombinant baculovirus infection of Sf21 cells in standard culture media (pH 6.2-6.4), properly processed Chikungunya structural proteins were detected and assembled capsids were observed. However, an increase in culture pH to 6.6-6.8 was necessary to produce detectable concentrations of assembled VLPs. Since this elevated production pH exceeds the optimum for growth medium stability and Sf21 culture, medium modifications were made and a novel insect cell variant (SfBasic) was derived by exposure of Sf21 to elevated culture pH for a prolonged period of time. The high-pH adapted SfBasic insect cell line described herein is capable of maintaining normal cell growth into the typical mammalian cell culture pH range of 7.0-7.2 and produces 11-fold higher Chikungunya VLP yields relative to the parental Sf21 cell line. After scale-up into stirred tank bioreactors, SfBasic derived VLPs were chromatographically purified and shown to be similar in size and structure to a VLP standard derived from transient gene expression in HEK293 cells. Total serum anti-Chikungunya IgG and neutralizing titers from guinea pigs vaccinated with SfBasic derived VLPs or HEK293 derived VLPs were not significantly different with respect to production method, suggesting that this adapted insect cell line and production process could be useful for manufacturing Chikungunya VLPs for use as a vaccine. The adaptation of Sf21 to produce high levels of recombinant protein and VLPs in an elevated pH range may also have applications for other pH-sensitive protein or VLP targets.
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
James M
JM
Wagner
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
J David
JD
Pajerowski
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Christopher L
CL
Daniels
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Patrick M
PM
McHugh
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Jessica A
JA
Flynn
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
John W
JW
Balliet
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Danilo R
DR
Casimiro
Vaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Shyamsundar
S
Subramanian
D000818:Animals; D002213:Capsid / Q000648:ultrastructure; D018929:Cell Culture Techniques; D002460:Cell Line; D002646:Chikungunya virus / Q000502:physiology*; D015870:Gene Expression; D006168:Guinea Pigs; D006801:Humans; D006863:Hydrogen-Ion Concentration; D011994:Recombinant Proteins; D018411:Spodoptera; D015678:Viral Structural Proteins / Q000235:genetics / Q000378:metabolism; D014771:Virion / Q000276:immunology / Q000648:ultrastructure; D014779:Virus Replication
D011994:Recombinant Proteins; D015678:Viral Structural Proteins